Share on StockTwits
 

Dechra Pharmaceuticals (LON:DPH) was upgraded by investment analysts at Nplus1 Brewin to a “buy” rating in a note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. The firm currently has a GBX 785 ($13.06) price objective on the stock, up from their previous price objective of GBX 740 ($12.31). Nplus1 Brewin’s target price would suggest a potential upside of 15.67% from the company’s current price.

Shares of Dechra Pharmaceuticals (LON:DPH) opened at 689.542 on Tuesday. Dechra Pharmaceuticals has a 52 week low of GBX 655.38 and a 52 week high of GBX 791.50. The stock’s 50-day moving average is GBX 699.4 and its 200-day moving average is GBX 695.1. The company’s market cap is £601.0 million.

Several other analysts have also recently commented on the stock. Analysts at N+1 Singer upgraded shares of Dechra Pharmaceuticals to a “buy” rating in a research note on Tuesday. They now have a GBX 785 ($13.06) price target on the stock, up previously from GBX 740 ($12.31). Separately, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note on Tuesday. They now have a GBX 800 ($13.30) price target on the stock. Finally, analysts at Oriel Securities Ltd reiterated a “hold” rating on shares of Dechra Pharmaceuticals in a research note on Tuesday, February 11th. They now have a GBX 690 ($11.48) price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dechra Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of GBX 775.71 ($12.90).

Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.